TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:24
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) https://www.brainstorm-cell.com
2.48USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-37.42%
BCLI
SPY
32.66%
-95.81%
BCLI
SPY
108.59%
-95.96%
BCLI
SPY
302.52%
-95.74%
BCLI
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
13.17
13.84
0.20
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.93
-24.07
-2.17
-99.66
0.00
-1.22
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-835.07
82.47
-2149.43
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.3808
1017.27
586.25
0.56
Other Earnings and Cash Flow Stats:
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Net Income TTM ($MM) is -14.23
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Operating Income TTM ($MM) is -13.31
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Owners' Earnings Annual ($MM) is 0.00
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Current Price to Owners' Earnings ratio is 0.00
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) EBITDA TTM ($MM) is -13.05
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) EBITDA Margin is -2149.43%
Capital Allocation:
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) has paid 0.00 dividends per share and bought back 38.942013 million shares in the past 12 months
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) has reduced its debt by 2.05 million USD in the last 12 months
Capital Structure:
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Interest-bearing Debt ($MM) as of last quarter is 0
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Annual Working Capital Investments ($MM) are 0
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Book Value ($MM) as of last quarter is -7
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Debt/Capital as of last quarter is -14%
Other Balance Sheet Stats:
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) has 0 million in cash on hand as of last quarter
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) has 7 million of liabilities due within 12 months, and long term debt 0 as of last quarter
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) has 5 common shares outstanding as of last quarter
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) has 0 million USD of preferred stock value
Academic Scores:
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Altman Z-Score is -176.20 as of last quarter
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) largest shareholder is MORGAN STANLEY owning 49463 shares at 0.12 ($MM) value
Lebovits Chaim(an insider) Bought 1836 shares of BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) for the amount of $6292.34 on 2024-10-01
9.04% of BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) is held by insiders, and 13.90% is held by institutions
BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) went public on 2003-08-28
Other BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) financial metrics:
FCF:-14.71
Unlevered Free Cash Flow:0.00
EPS:-0.14
Operating Margin:-835.07
Gross Profit Margin:82.47
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:178.83
Beta:0.56
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BRAINSTORM CELL THERAPEUTICS INC. ( BCLI ) :
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.